Blueprint adds CONNEQT Pulse to its Protocol Marketplace

On 10 September 2026, Stockhead/The Australian reported that CONNEQT Health entered a commercial marketing agreement with Blueprint. The deal places CONNEQT Pulse in Blueprint’s Protocol Marketplace, with a dedicated product page, referral links and promotional offers. The report describes Pulse as an FDA-cleared arterial-health monitor and says customers buy directly from CONNEQT. It also repeats Blueprint’s statement that marketplace products are reviewed by Johnson’s doctors and longevity researchers and must meet Blueprint Certified standards. The announcement reports no randomized trial, diagnostic-accuracy comparison, adherence data, adverse-event analysis or change in a longevity-relevant outcome from the partnership. A listing and referral arrangement can increase access and visibility, but it does not establish that the device improves vascular health, prevents cardiovascular events or slows aging. The Australian article was readable in search metadata but blocked by the page-fetcher’s robots policy; the exact URL resolves in search, and the underlying company announcement is corroborated by CONNEQT’s public market release dated 7 September 2026. Because the partnership is commercial, the marketplace’s quality language should be read as a claim requiring independent verification, not as clinical evidence.

No clinical conclusion is reported; the announcement concerns distribution and promotion of the device.